These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 29653557)

  • 41. Clinical characteristics and symptom burden of Thai myeloproliferative neoplasm patients.
    Cherdchoo N; Polprasert C; Rojnuckarin P; Kongkiatkamon S
    Hematology; 2023 Dec; 28(1):2280731. PubMed ID: 37942783
    [No Abstract]   [Full Text] [Related]  

  • 42. Assessing disease burden in patients with classic MPNs.
    Geyer H; Mesa RA
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):107-19. PubMed ID: 25189722
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
    Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
    Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
    [No Abstract]   [Full Text] [Related]  

  • 44. Epidemiology of myeloproliferative neoplasms in the United States.
    Mehta J; Wang H; Iqbal SU; Mesa R
    Leuk Lymphoma; 2014 Mar; 55(3):595-600. PubMed ID: 23768070
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms.
    Krečak I; Gverić-Krečak V; Lapić I; Rončević P; Gulin J; Fumić K; Krečak F; Holik H; Duraković N
    Acta Clin Belg; 2021 Feb; 76(1):32-39. PubMed ID: 31455178
    [No Abstract]   [Full Text] [Related]  

  • 46. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.
    Geyer HL; Scherber RM; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Vannucchi AM; Passamonti F; Samuelsson J; Birgegard G; Mesa RA
    Blood; 2014 Jun; 123(24):3803-10. PubMed ID: 24553173
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms.
    Ferrari A; Scandura J; Masciulli A; Krichevsky S; Gavazzi A; Barbui T
    Eur J Haematol; 2021 Feb; 106(2):250-259. PubMed ID: 33135220
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Work impairment, osteoarthritis, and health-related quality of life among employees in Japan.
    Nakata K; Tsuji T; Vietri J; Jaffe DH
    Health Qual Life Outcomes; 2018 Apr; 16(1):64. PubMed ID: 29665820
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Analysis of the MPN Landmark survey for impact and perceptions of treatment goals among Chinese physicians and myeloproliferative neoplasm patients].
    Xu ZF; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):570-575. PubMed ID: 32810964
    [No Abstract]   [Full Text] [Related]  

  • 50. The personal impact of living with a myeloproliferative neoplasm.
    Eppingbroek AAM; Lechner L; Bakker EC; Nijkamp MD; de Witte MA; Bolman CAW
    Psychooncology; 2024 Apr; 33(4):e6338. PubMed ID: 38610117
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Psychological Symptoms Among Patients With BCR-ABL-Negative Myeloproliferative Neoplasms.
    McFarland DC; Polizzi H; Mascarenhas J; Kremyanskaya M; Holland J; Hoffman R
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1563-1570. PubMed ID: 27956541
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.
    Htun HL; Lian W; Wong J; Tan EJ; Foo LL; Ong KH; Lim WY
    Cancer Epidemiol; 2022 Aug; 79():102175. PubMed ID: 35569302
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Validity of the work productivity and activity impairment questionnaire--general health version in patients with rheumatoid arthritis.
    Zhang W; Bansback N; Boonen A; Young A; Singh A; Anis AH
    Arthritis Res Ther; 2010; 12(5):R177. PubMed ID: 20860837
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms.
    Abelsson J; Andréasson B; Samuelsson J; Hultcrantz M; Ejerblad E; Johansson B; Emanuel R; Mesa R; Johansson P
    Leuk Lymphoma; 2013 Oct; 54(10):2226-30. PubMed ID: 23398206
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Myeloproliferative neoplasms (MPNs) - Part 2: A nursing guide to managing the symptom burden of MPNs.
    Fowlkes S; Murray C; Fulford A; De Gelder T; Siddiq N
    Can Oncol Nurs J; 2018; 28(4):276-281. PubMed ID: 31148831
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study.
    Pedersen KM; Bak M; Sørensen AL; Zwisler AD; Ellervik C; Larsen MK; Hasselbalch HC; Tolstrup JS
    Cancer Med; 2018 Nov; 7(11):5796-5802. PubMed ID: 30318865
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.
    Dentali F; Ageno W; Rumi E; Casetti I; Poli D; Scoditti U; Maffioli M; di Minno MN; Caramazza D; Pietra D; De Stefano V; Passamonti F
    Thromb Res; 2014 Jul; 134(1):41-3. PubMed ID: 24787989
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
    Geyer HL; Kosiorek H; Dueck AC; Scherber R; Slot S; Zweegman S; Te Boekhorst PA; Senyak Z; Schouten HC; Sackmann F; Fuentes AK; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Döhner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Paoli C; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Cannon K; Birgegard G; Xiao Z; Xu Z; Zhang Y; Sun X; Xu J; Kiladjian JJ; Zhang P; Gale RP; Mesa RA
    Haematologica; 2017 Jan; 102(1):85-93. PubMed ID: 27540137
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of Dry Eye Disease on Work Productivity, and Patients' Satisfaction With Over-the-Counter Dry Eye Treatments.
    Nichols KK; Bacharach J; Holland E; Kislan T; Shettle L; Lunacsek O; Lennert B; Burk C; Patel V
    Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):2975-82. PubMed ID: 27273596
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Myeloproliferative neoplasms (MPNs) - Part 1: An overview of the diagnosis and treatment of the "classical" MPNs.
    Fowlkes S; Murray C; Fulford A; De Gelder T; Siddiq N
    Can Oncol Nurs J; 2018; 28(4):262-268. PubMed ID: 31148835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.